Improved Prediction Accuracy for Late-Onset Preeclampsia Using cfRNA Profiles: A Comparative Study of Marker Selection Strategies DOI Open Access

Akira Nakano,

Kohei Uno, Yusuke Matsui

et al.

Healthcare, Journal Year: 2025, Volume and Issue: 13(10), P. 1162 - 1162

Published: May 16, 2025

Background: Late-onset pre-eclampsia (LO-PE) remains difficult to predict because placental angiogenic markers perform poorly once maternal cardiometabolic factors dominate. Methods: We reanalyzed a publicly available cell-free RNA (cfRNA) cohort (12 EO-PE, 12 LO-PE, and 24 matched controls). After RNA-seq normalization, we derived LO-PE candidate genes using (i) differential expression (ii) elastic-net feature selection. Predictive accuracy was assessed with nested Monte-Carlo cross-validation (10 × 70/30 outer splits; 5-fold inner grid-search for λ). Results: The best model achieved mean ± SD AUROC of 0.88 0.08 F1 0.73 0.17—substantially higher than an EO-derived baseline applied the same samples (AUROC ≈ 0.69). Enrichment analysis highlighted immune-tolerance metabolic pathways; three (HLA-G, IL17RB, KLRC4) recurred across >50% repeats. Conclusions: Plasma cfRNA signatures can outperform existing EO-based screens nominate biologically plausible immune dysregulation. Because present dataset is small (n = 48) underpowered single-gene claims, external validation in larger, multicenter cohorts essential before clinical translation.

Language: Английский

A comparative study of co-morbidities and outcomes between HELLP syndrome and severe pre-eclampsia without HELLP syndrome in a tertiary care centre DOI Open Access

Preeti F. Lewis,

Vaishnavi Surpatne,

Rucha Bendale

et al.

International Journal of Reproduction Contraception Obstetrics and Gynecology, Journal Year: 2025, Volume and Issue: 14(3), P. 780 - 785

Published: Feb. 26, 2025

Background: Pre-eclampsia is a pregnancy specific, multi-system, life-threatening complication. Incidence of severe pre-eclampsia varies between 10-20% all pregnancies and that HELLP syndrome 0.2-0.6% pregnancies. This study aims to provide comprehensive view maternal perinatal outcomes in without HELLP. Methods: prospective, observational, comparative was conducted at tertiary care centre- Grant medical college sir JJ group hospitals, period 10 months (March 2024 December 2024). 30 patients with features were compared syndrome. The studied results analysed. Results: complications the need for blood products transfusion greater However, only marginal differences noted outcomes. Conclusions: associated increased morbidity mortality as pre-eclampsia. Only neonatal due preeclampsia Aggressive timely treatment these conditions helps reducing mortality.

Language: Английский

Citations

0
Improved Prediction Accuracy for Late-Onset Preeclampsia Using cfRNA Profiles: A Comparative Study of Marker Selection Strategies DOI Open Access

Akira Nakano,

Kohei Uno, Yusuke Matsui

et al.

Healthcare, Journal Year: 2025, Volume and Issue: 13(10), P. 1162 - 1162

Published: May 16, 2025

Background: Late-onset pre-eclampsia (LO-PE) remains difficult to predict because placental angiogenic markers perform poorly once maternal cardiometabolic factors dominate. Methods: We reanalyzed a publicly available cell-free RNA (cfRNA) cohort (12 EO-PE, 12 LO-PE, and 24 matched controls). After RNA-seq normalization, we derived LO-PE candidate genes using (i) differential expression (ii) elastic-net feature selection. Predictive accuracy was assessed with nested Monte-Carlo cross-validation (10 × 70/30 outer splits; 5-fold inner grid-search for λ). Results: The best model achieved mean ± SD AUROC of 0.88 0.08 F1 0.73 0.17—substantially higher than an EO-derived baseline applied the same samples (AUROC ≈ 0.69). Enrichment analysis highlighted immune-tolerance metabolic pathways; three (HLA-G, IL17RB, KLRC4) recurred across >50% repeats. Conclusions: Plasma cfRNA signatures can outperform existing EO-based screens nominate biologically plausible immune dysregulation. Because present dataset is small (n = 48) underpowered single-gene claims, external validation in larger, multicenter cohorts essential before clinical translation.

Language: Английский

Citations

0